TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-Managed Walking Improves Function in Patients With Diabetes Mellitus and Peripheral Arterial Disease
Brief Summary: We are conducting a clinical research trial to determine the role of self-managed walking therapy to improve walking ability in patients with diabetes mellitus and peripheral arterial disease (PAD). PAD, commonly referred to as poor circulation in the legs, is a very common disease in patients with diabetes mellitus. For patients with PAD, there is a significant risk for poor walking ability and limb loss. One major treatment for PAD is walking therapy but the traditional methods for the delivery of this treatment have required frequent visits to a university or hospital-based site. We will address the role of self-managed walking program, to be conducted at or near the home, to improve limb function.


Options:
A: Arm Label: The experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Group walking and group educational workshops | Arm Label: The control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group walking and group educational workshops; Assigned to Arm(s): The experimental group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Self-managed walking | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Self-managed walking; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A
D: Arm Label: Resistance Training; Type: EXPERIMENTAL; Interventions: Behavioral: Resistance Training | Arm Label: Aerobic Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise | Arm Label: Combination RT & AT; Type: EXPERIMENTAL; Interventions: Behavioral: Combo | Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: Continued Sedentary lifestyle | Intervention Type: BEHAVIORAL; Name: Resistance Training; Assigned to Arm(s): Resistance Training | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise; Assigned to Arm(s): Aerobic Exercise | Intervention Type: BEHAVIORAL; Name: Combo; Assigned to Arm(s): Combination RT & AT | Intervention Type: BEHAVIORAL; Name: Continued Sedentary lifestyle; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-Managed Walking Improves Function in Patients With Diabetes Mellitus and Peripheral Arterial Disease
Brief Summary: We are conducting a clinical research trial to determine the role of self-managed walking therapy to improve walking ability in patients with diabetes mellitus and peripheral arterial disease (PAD). PAD, commonly referred to as poor circulation in the legs, is a very common disease in patients with diabetes mellitus. For patients with PAD, there is a significant risk for poor walking ability and limb loss. One major treatment for PAD is walking therapy but the traditional methods for the delivery of this treatment have required frequent visits to a university or hospital-based site. We will address the role of self-managed walking program, to be conducted at or near the home, to improve limb function.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Self-managed walking | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Self-managed walking; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control--Resistance Training | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Control--Resistance Training; Assigned to Arm(s): 3
C: Arm Label: Best medical treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Supervised exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised exercise training | Intervention Type: BEHAVIORAL; Name: Supervised exercise training; Assigned to Arm(s): Supervised exercise training
D: Arm Label: Angioplasty / surgery and exercise therapy; Type: EXPERIMENTAL; Interventions: Procedure: Angioplasty / surgery and exercise therapy | Arm Label: Angioplasty / surgery; Type: NO_INTERVENTION; Interventions: Procedure: angioplasty / surgery | Intervention Type: PROCEDURE; Name: angioplasty / surgery; Assigned to Arm(s): Angioplasty / surgery | Intervention Type: PROCEDURE; Name: Angioplasty / surgery and exercise therapy; Assigned to Arm(s): Angioplasty / surgery and exercise therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-Managed Walking Improves Function in Patients With Diabetes Mellitus and Peripheral Arterial Disease
Brief Summary: We are conducting a clinical research trial to determine the role of self-managed walking therapy to improve walking ability in patients with diabetes mellitus and peripheral arterial disease (PAD). PAD, commonly referred to as poor circulation in the legs, is a very common disease in patients with diabetes mellitus. For patients with PAD, there is a significant risk for poor walking ability and limb loss. One major treatment for PAD is walking therapy but the traditional methods for the delivery of this treatment have required frequent visits to a university or hospital-based site. We will address the role of self-managed walking program, to be conducted at or near the home, to improve limb function.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 3
B: Arm Label: Intermittent claudication; Type: N/A; Interventions: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Self-managed walking | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Self-managed walking; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group mediated cognitive behavioral (GMCB) sessions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions | Intervention Type: BEHAVIORAL; Name: Group mediated cognitive behavioral (GMCB) sessions; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Health education sessions; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Effect of Eszoplicone on Initial Continuous Positive Airway Pressure (CPAP) Compliance
Brief Summary: The purpose of this study is to assess the efficacy of Eszopiclone in improving short and intermediate-term compliance with continuous positive airway pressure (CPAP) in patients newly diagnosed with obstructive sleep apnea (OSA).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Losartan | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Losartan | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Losartan, Other: CPAP | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): 1, 2, 3 | Intervention Type: OTHER; Name: CPAP; Assigned to Arm(s): 3
B: Arm Label: TLC-CPAP; Type: EXPERIMENTAL; Interventions: Device: Telecommunications system | Arm Label: TLC-Control; Type: PLACEBO_COMPARATOR; Interventions: Other: TLC-Control | Intervention Type: DEVICE; Name: Telecommunications system; Assigned to Arm(s): TLC-CPAP | Intervention Type: OTHER; Name: TLC-Control; Assigned to Arm(s): TLC-Control
C: Arm Label: OSA CPAP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo control | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): OSA CPAP | Intervention Type: DRUG; Name: Placebo control; Assigned to Arm(s): Placebo
D: Arm Label: Sleep Unit group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Primary Care group; Type: EXPERIMENTAL; Interventions: Other: Clinical follow up by general practitioners in primary care | Intervention Type: OTHER; Name: Clinical follow up by general practitioners in primary care; Assigned to Arm(s): Primary Care group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 14-week, Randomized, Double-blind, Placebo-controlled, Multi-center Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily (O.D.) in Patients With Fibromyalgia
Brief Summary: This is a study to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients. A previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.


Options:
A: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minalcipran; Type: EXPERIMENTAL; Interventions: Drug: milnacipran | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: cognitive behavioral therapy | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride, Behavioral: cognitive behavioral therapy | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: benztropine mesylate 0.125 mg daily | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: benztropine mesylate 0.125 mg daily; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 1
D: Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 4; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Use of Fixed Doses of Artesunate Plus Amodiaquine Combination for the Home Management of Presumed Malaria in Malagasy Children
Brief Summary: The purpose of this study is to assess the feasibility, the acceptability and the effectiveness of the use of the Artesunate + Amodiaquine Fixed Dose Combination for the home management of presumed malaria in Malagasy children by the community-based service providers.


Options:
A: Intervention Type: DEVICE; Name: Rapid Diagnostic Test for P. falciparum malaria; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Microscopy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clinical diagnosis for malaria | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Rapid diagnostic test | Intervention Type: PROCEDURE; Name: Rapid diagnostic test; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Microscopy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Clinical diagnosis for malaria; Assigned to Arm(s): 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Intervention Type: DRUG; Name: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Observation; Type: N/A; Interventions: Drug: Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam) | Intervention Type: DRUG; Name: Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam); Assigned to Arm(s): Observation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A One Year, Multi-center, Randomised, Double-blind Placebo-controlled Parallel-groups Assessment of the Tolerability, Safety and Efficacy of Epanova Soft Gelatin Capsules 4g/Day for Maintenance of Remission of Crohn's Disease.
Brief Summary: The primary objective of this study is to assess the ability of EpanovaTM Soft Gelatin Capsules at a total daily dose of 4g (4x 1g capsules) to maintain remission (Crohn's Disease Activity Index CDAI \< 150) in CD patients in whom remission, stable for at least three months and no longer than one year, has been induced by corticosteroids, azathioprine/6-MP, methotrexate, 5-ASA or antibiotics.

Secondary objectives are to assess the:

efficacy of Epanova versus placebo by Crohn's Disease Activity Index (CDAI), Investigator and Subject Global Ratings, employment status and use of CD related medical visits in subjects with CD in remission

safety and tolerability of Epanova

ability of Epanova to maintain the quality of life of CD patients in remission


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: 1 Epanova; Type: EXPERIMENTAL; Interventions: Drug: Epanova | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epanova | Intervention Type: DRUG; Name: Epanova; Assigned to Arm(s): 1 Epanova, 2 Placebo
C: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A One Year, Multi-center, Randomised, Double-blind Placebo-controlled Parallel-groups Assessment of the Tolerability, Safety and Efficacy of Epanova Soft Gelatin Capsules 4g/Day for Maintenance of Remission of Crohn's Disease.
Brief Summary: The primary objective of this study is to assess the ability of EpanovaTM Soft Gelatin Capsules at a total daily dose of 4g (4x 1g capsules) to maintain remission (Crohn's Disease Activity Index CDAI \< 150) in CD patients in whom remission, stable for at least three months and no longer than one year, has been induced by corticosteroids, azathioprine/6-MP, methotrexate, 5-ASA or antibiotics.

Secondary objectives are to assess the:

efficacy of Epanova versus placebo by Crohn's Disease Activity Index (CDAI), Investigator and Subject Global Ratings, employment status and use of CD related medical visits in subjects with CD in remission

safety and tolerability of Epanova

ability of Epanova to maintain the quality of life of CD patients in remission


Options:
A: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
B: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
C: Arm Label: 1 Epanova; Type: EXPERIMENTAL; Interventions: Drug: Epanova | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epanova | Intervention Type: DRUG; Name: Epanova; Assigned to Arm(s): 1 Epanova, 2 Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Prophylactic Misoprostol Prior to Intrauterine Device Insertion
Brief Summary: The purpose of this study is to see if using misoprostol (a medication that softens the cervix) before placing an intrauterine device for contraception reduces pain in women who have never delivered a baby.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Magnesium Oxide | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DIETARY_SUPPLEMENT; Name: Magnesium Oxide; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Immediate IUD insertion | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Immediate IUD insertion; Assigned to Arm(s): 1
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Levonorgestrel (Mirena, BAY86-5028) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cytotec | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Levonorgestrel (Mirena, BAY86-5028); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Cytotec; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
D: Arm Label: Oxygen (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Procedure: IUD insertion, Drug: Povidone-Iodine, Drug: Chlorhexidine, Other: Oxygen | Arm Label: Nitrous Oxide (NO); Type: EXPERIMENTAL; Interventions: Procedure: IUD insertion, Drug: Povidone-Iodine, Drug: Chlorhexidine, Other: Nitrous oxide | Intervention Type: PROCEDURE; Name: IUD insertion; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: DRUG; Name: Povidone-Iodine; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: DRUG; Name: Chlorhexidine; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: OTHER; Name: Oxygen; Assigned to Arm(s): Oxygen (Placebo) | Intervention Type: OTHER; Name: Nitrous oxide; Assigned to Arm(s): Nitrous Oxide (NO)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Plus Activity Strategy Training for Older Adults With Osteoarthritis
Brief Summary: Purpose: To study the effects of two different rehabilitation programs for people with osteoarthritis of the hip or knee.

Hypothesis 1: Participants who received Activity Stratgey Training will report less pain and physical disability at 8-weeks and 6-months follow-up.

Hypothesis 2: Participants who receive Activity Strategy Training will have a greater increase in physical activity as measured by a wrist-worn accelerometer.

Hypothesis 3: Participants who receive Activity Stratgey Training will report greater improvements in health-related quality of life.


Options:
A: Arm Label: Patient education programme; Type: EXPERIMENTAL; Interventions: Other: Patient education programme | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient education programme; Assigned to Arm(s): Patient education programme
B: Arm Label: Health Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Arm Label: Usual Medical Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Osteoarthritis Self-Management; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoarthritis Self-Management | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): Health Education Intervention | Intervention Type: BEHAVIORAL; Name: Osteoarthritis Self-Management; Assigned to Arm(s): Osteoarthritis Self-Management
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Patient Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Behavioral Intervention for OA | Arm Label: Provider Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Provider Intervention for OA | Arm Label: Patient and Provider Interventions; Type: EXPERIMENTAL; Interventions: Behavioral: Combined Patient and Provider Interventions for OA | Intervention Type: BEHAVIORAL; Name: Patient Behavioral Intervention for OA; Assigned to Arm(s): Patient Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Provider Intervention for OA; Assigned to Arm(s): Provider Intervention | Intervention Type: BEHAVIORAL; Name: Combined Patient and Provider Interventions for OA; Assigned to Arm(s): Patient and Provider Interventions
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Activity Strategy Training | Intervention Type: BEHAVIORAL; Name: Activity Strategy Training; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): 1

Answer: D